Powerful Responses
Consistent Results
Adults with previously treated MCL achieved deep responses for nearly 3 years
84% of patients responded to BRUKINSA
across both studies1
Initial analysis (18 months)1,2
Median follow-up time was 18.4 months for
Study 206 and 18.8 months
84% of patients responded to BRUKINSA
in the long-term analysis*3
Of those patients who responded,
93% (67/72) achieved a CR.3
Long-term analysis (35 months)
Median follow-up time in the long-term analysis
was 35.3 months for Study 206.3
*Exploratory analysis.
The efficacy of BRUKINSA was assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Tumor response was according to the 2014 Lugano classification for both studies, and the primary efficacy endpoint was ORR. Study BGB-3111-206 (Study 206): N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=32, Phase 1/2, open-label, global, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed mostly using CT scans.
Most patients responded for more
than 18 months
Initial analysis (18 months)1,2
Median follow-up time was 18.4 months for
Study 206 and 18.8 months for Study 003.2
Most patients experienced sustained
results for nearly 3 years3
Median time to response
For Study 206, median follow-up time for long-term analysis was 35.3 months.3
The efficacy of BRUKINSA was assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Tumor response was according to the 2014 Lugano classification for both studies, and the primary efficacy endpoint was ORR. Study BGB-3111-206 (Study 206): N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=32, Phase 1/2, open-label, global, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed mostly using CT scans.
CI=confidence interval; CR=complete response; CT=computed tomography; DOR=duration of response; IRC=independent review committee; MCL=mantle cell lymphoma; NCCN®=National Comprehensive Cancer Network®; NE=not estimable; ORR=overall response rate; PET=positron emission tomography; PR=partial response.
Zanubrutinib (BRUKINSA®) is included as a Category 2A preferred treatment option for second-line and subsequent therapy for MCL in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)4
